Summary
Cardinal Health, Inc. (CAH) announced a key board appointment in its recent 8-K filing. Robert W. Azelby has been elected to the Board of Directors, effective March 1, 2024. Mr. Azelby brings a background as the former President and Chief Executive Officer of Eliem Therapeutics, Inc., a biotechnology firm. His appointment is expected to enhance the Board's expertise, particularly with his inclusion on the Risk Oversight Committee. This appointment is effective until the upcoming 2024 annual shareholder meeting. The company confirmed that Mr. Azelby meets the independence requirements set by the NYSE and SEC. His compensation will align with that of other non-employee directors. This move suggests a continued focus on strengthening board governance and risk management as the company navigates its strategic objectives.
Key Highlights
- 1Cardinal Health appointed Robert W. Azelby to its Board of Directors, effective March 1, 2024.
- 2Mr. Azelby will serve until the 2024 annual shareholder meeting.
- 3He has been appointed to the Board's Risk Oversight Committee.
- 4Mr. Azelby's background includes serving as President and CEO of Eliem Therapeutics, Inc.
- 5The company has determined that Mr. Azelby is independent according to NYSE and SEC rules.
- 6Mr. Azelby will receive compensation consistent with other non-employee directors.
- 7The appointment was announced via a news release furnished as an exhibit to the 8-K.